Name | N-ethyl-5'-carboxamidoadenosine |
---|---|
Synonyms |
(2S,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide (non-preferred name)
(2S,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide (non-preferred name) 5’-Ethylcarboxamido Adenosine MFCD00069195 5'-Ethylcarboxamido Adenosine 1-(6-AMINO-9H-PURIN-9-YL)-1-DEOXY-N-ETHYL-β-D-RIBOFURANURONAMIDE β-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl- 5'-(N-Ethylcarboxamido)adenosine NECA |
Description | 5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist. |
---|---|
Related Catalog | |
Target |
Adenosine receptor[1] |
In Vivo | After the administration of 5'-N-Ethylcarboxamidoadenosine (NECA), the mean number of cocaine infusions obtained per session is decreased significantly in a dose-dependent manner [5'-N-Ethylcarboxamidoadenosine (NECA): F(4,12)=14.9; P<0.001]. The administration of 5'-N-Ethylcarboxamidoadenosine (NECA) [F(4,12)=16.1; P<0.001] results in a significant increase in latencies above values obtained for vehicle treatment[1]. Daily i.p. injection of 5'-N-Ethylcarboxamidoadenosine (NECA) at 0.3 mg/kg/day for two weeks reduces malondialdehyde (MDA) levels in diabetic rats, but does not affect control rats. Daily treatment with NECA (0.3 mg/kg/day, i.p. for two weeks) reduces diabetes-induced gene expression of tumor necrosis factor (TNF)-α and interleukin (IL)-18 in diabetic rats, but does not affect control rats. Daily i.p. injection of 5'-N-Ethylcarboxamidoadenosine (NECA) at 0.3 mg/kg/day for two weeks also blocks the activation of JNK MAPK in diabetic rats, but does not affect control rats[2]. |
Animal Admin | Male Wistar rats are used in this experiment. These animals range in weight between 350 and 425 g. They are housed individually in hanging wire cages under a 12-h light/dark cycle. The effects of 5'-N-Ethylcarboxamidoadenosine (NECA) are tested in four rats. In the experiment, either 5'-N-Ethylcarboxamidoadenosine (NECA) (5, 7.5, 10, 20 μg/kg) or vehicle (saline) is administered intraperitoneally 15 min prior to the start of test sessions. 5'-N-Ethylcarboxamidoadenosine (NECA) is administered following a random order crossover design. In most cases, animals are tested twice with the same dose[1]. |
References |
Density | 1.9±0.1 g/cm3 |
---|---|
Melting Point | 229-231ºC |
Molecular Formula | C12H16N6O4 |
Molecular Weight | 308.293 |
Exact Mass | 308.123291 |
PSA | 148.41000 |
LogP | -0.48 |
Index of Refraction | 1.829 |
Water Solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.2 mg/mL Solutions may be stored for several days at 4?#x00b0;C. |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H300 |
Precautionary Statements | P264-P301 + P310 |
Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
Hazard Codes | T+: Very toxic; |
Risk Phrases | R28 |
Safety Phrases | 22-26-36-45 |
RIDADR | UN 2811 6.1/PG 2 |
WGK Germany | 3 |
RTECS | VJ2232000 |
Packaging Group | I |
Hazard Class | 6.1(a) |
HS Code | 2934999090 |
Precursor 7 | |
---|---|
DownStream 1 | |
HS Code | 2934999090 |
---|---|
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |